A British mitochondrial startup wants to break ground in ALS and Parkinson’s. It has £50M to try
Endpoints News Read more
Mitochondria: Movers and Shakers – a podcast about life with Parkinson’s
Apple Podcasts Listen more
Novel Parkinson’s therapy protects mitochondrial function
Drug Discovery World Read more
NRG Therapeutics launches Series B after $5m boost from Michael J. Fox Foundation
Business Weekly Read more
NRG Therapeutics gets grant to test mitochondria-targeting ALS therapy
ALS News Today Read more
Case Study: Life Sciences – Future50
PwC Read more (pdf)
9 neuroscience biotech companies you should know about
Labiotech Read more
MJFF grant supports NRG Therapeutics’ work to validate mitochondrial drug target for Parkinson’s
Bioworld Read more
Case Study: R&D grant funding
BIA, UK BioIndustry Association Read more
Parkinson’s disease drug hunters think outside the α-synuclein box
Nature Biotechnology Read more (behind paywall)
© NRG Therapeutics
